Zobrazeno 1 - 10
of 33
pro vyhledávání: ''
Autor:
Yukio Miki, Kohei Kotani, Kanako Yoshida, Kenjiro Kimura, Naoshi Odagiri, Sawako Uchida-Kobayashi, Akihiro Tamori, Hiroko Ikenaga, Shoji Kubo, Atsushi Hagihara, Ken Kageyama, Masaru Enomoto, Norifumi Kawada, Akira Yamamoto, Hideki Fujii
Publikováno v:
Oncology. 99(3):186-191
Introduction: Lenvatinib has been approved as a systemic therapy for patients with unresectable hepatocellular carcinoma (HCC). We recently experienced lenvatinib-induced tumor-related hemorrhage in patients with HCC. The full details of tumor-relate
Autor:
Alla Berlin, Leora Brazg Ferro, Ester Osher, Orit Gutfeld, Inbal Golomb, Inna Ospovat, Viacheslav Soyfer, Ido Wolf, Shira Peleg Hasson
Publikováno v:
Oncology. 99:373-379
Introduction: Extrapulmonary small-cell cancer (EPSCC) is a relatively rare malignancy. The management of EPSCC is usually extrapolated from small-cell lung cancer (SCLC). In spite of the morphological similarity of the 2 malignancies, there are many
Autor:
Hitomi Sezaki, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Fumitaka Suzuki, Tetsuya Hosaka, Yoshiyuki Suzuki, Masahiro Kobayashi, Yusuke Kawamura, Satoshi Saitoh, Shunichiro Fujiyama, Hiromitsu Kumada, Norio Akuta
Publikováno v:
Oncology. 99:114-123
Introduction: It remains unclear whether TERT promoter mutation (TERT C228T) in serum cell-free DNA (cfDNA) is useful for the diagnosis of hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease (NAFLD). Methods: In this retr
Autor:
Masahiro Noda, Takaaki Arigami, Hiroshi Kurahara, Daisuke Matsushita, Satoshi Iino, Keishi Okubo, Yoshiaki Kita, Yoshikazu Uenosono, Yota Kawasaki, Shigehiro Yanagita, Sumiya Ishigami, Kosei Maemura, Shinichiro Mori, Ken Sasaki, Shoji Natsugoe
Publikováno v:
Oncology. 98:273-279
Objective: Chemotherapy is generally recommended as the first-line standard treatment in patients with liver metastasis from gastric cancer. However, the clinical impact of surgical treatment remains unclear in responders after chemotherapy. The pres
Autor:
Hiroshi Matsushita, Kazuhiro Nouso, Hiroyuki Terasawa, Takuya Adachi, Soichiro Ako, Yasuto Takeuchi, Mari Mandai, Akinobu Takaki, Hideki Onishi, Hidenori Shiraha, Tetsushige Mimura, Hideaki Kinugasa, Nozomu Wada, Hiroyuki Okada, Fusao Ikeda, Shinichi Fujioka
Publikováno v:
Oncology. 98:311-317
Background: Mutations in the human telomerase reverse transcriptase (hTERT) gene promoter have been reported in hepatocellular carcinoma (HCC); however, analyses of these mutations in liquid biopsies have been technically difficult because of the hig
Autor:
Hiroshi Shibata, Takashi Kumada, Kazuto Tajiri, Michitaka Imai, Masashi Hirooka, Atsushi Hiraoka, Norio Itokawa, Kunihiko Tsuji, Taeang Arai, Masatoshi Kudo, Kojiro Michitaka, Kazuya Kariyama, Shinya Fukunishi, Korenobu Hayama, Shinichiro Nakamura, Ei Itobayashi, Toru Ishikawa, Hironori Ochi, Yoichi Hiasa, Hideko Ohama, Akemi Tsutsui, Toshifumi Tada, Koichi Takaguchi, Masanori Atsukawa, Kazuhito Kawata, Noritomo Shimada, Hidenori Toyoda
Publikováno v:
Oncology. 98:295-302
Background/Aim: Few studies have examined the details of nutritional status in patients with unresectable hepatocellular carcinoma (u-HCC) undergoing systemic chemotherapy with lenvatinib. We evaluated the prognostic/predictive value of nutritional s
Autor:
Yoshinari Asaoka, Tetsuo Ushiku, Jun Kinoshita, Yoshiumi Ouchi, Masamichi Koike, Ryosuke Tateishi, Junji Shibahara, Masashi Fukayama, Akimasa Hayashi, Kazuhiko Koike, Shuichiro Shiina
Publikováno v:
Oncology. 98:186-194
Background:The clinical course of hepatocellular carcinoma (HCC) is complicated, because it often recurs and shows multiple lesions, some of which progress to a more malignant form, shortening the life of the patient. The hepatocyte growth factor rec
Autor:
Kazuki Ohya, Kazuaki Chayama, Tomokazu Kawaoka, Masami Yamauchi, Maiko Namba, Takashi Nakahara, Michio Imamura, Kei Morio, Eisuke Murakami, Kenichiro Kodama, Shinsuke Uchikawa, Akira Hiramatsu, Hiroshi Aikata
Publikováno v:
Oncology. 97:75-81
Aim: This study investigated early tumor marker response and treatment response in patients with advanced hepatocellular carcinoma (HCC) treated with lenvatinib. Methods: Twenty patients with advanced HCC who received lenvatinib were enrolled in this
Autor:
Masatoshi Tanaka, Toshi Abe, Naoki Kamachi, Mika Nomiyama, Ryoko Kuromatsu, Masahito Nakano, Takashi Niizeki, Hiroyuki Suzuki, Hideki Iwamoto, Takuji Torimura, Etsuyo Ogo, Manabu Satani, Syusuke Okamura, Hironori Koga, Shigeo Shimose, Miwa Sakai, Yu Noda, Tomotake Shirono
Publikováno v:
Oncology. 96:192-199
Aim: Prognosis of hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) is extremely poor. However, proper therapeutic strategies have not been established yet. The purpose of this study is to identify the effects of external beam radiatio
Autor:
Noritomo Shimada, Yoichi Hiasa, Kazuhito Kawata, Akemi Tsutsui, Satoshi Yasuda, Takuya Nagano, Masashi Hirooka, Kazuto Tajiri, Ei Itobayashi, Atsushi Hiraoka, Norio Itokawa, Yohei Koizumi, Kunihiko Tsuji, Toshifumi Tada, Shinichiro Nakamura, Kazuhiro Nouso, Toru Ishikawa, Taeang Arai, Michitaka Imai, Kojiro Michitaka, Shinya Fukunishi, Tomomi Okubo, Takashi Kumada, Kouji Joko, Hidenori Toyoda, Hideko Ohama, Hironori Ochi, Hiroshi Shibata, Koichi Takaguchi, Masanori Atsukawa, Kazuya Kariyama
Publikováno v:
Oncology. 99(8)
Aim/Background: Transarterial chemoembolization (TACE) is recommended for patients with intermediate-stage hepatocellular carcinoma (HCC). In this study, we investigated the impact of early lenvatinib administration in patients with intermediate-stag